A new cervical cancer treatment is showing promise in boosting survival rates and reducing recurrence What this breakthrough means for patients.

Cervical cancer is the fourth most common cancer among women worldwide. In India, where it is the second most common, it ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Joining a clinical trial for cervical cancer opens the door to new treatments that could have life-changing effects.

Cervical cancer is the leading cause of cancer-related deaths among women worldwide, with around 6, 60,000 new cases and 3,50,000 deaths each year. India contributes around 25% of this global burden.

as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The approval means ...

Cervical cancer is caused by human papillomavirus HPV and has become a major health concern Read this article to know ...

The Federal Capital Territory Administration (FCTA) has acquired its first colposcopy machine, marking a significant step in combating cervical cancer and improving health outcomes in the region ...